Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease. uri icon

authors

  • Wang, Guoqiao
  • Benzinger, Tammie L S
  • Gordon, Brian A
  • Fagan, Anne M
  • Coalier, Kelley A
  • Libre-Guerra, Jorge J
  • McCullough, Austin
  • Joseph-Mathurin, Nelly
  • Chen, Charles D
  • Mummery, Catherine
  • Wendelberger, Barbara A
  • Li, Yan
  • Gauthier, Serge
  • Masellis, Mario
  • Holdridge, Karen C
  • Yaari, Roy
  • Chatterjee, Saptarshi
  • Sims, John
  • Delmar, Paul
  • Kerchner, Geoffrey A
  • Bittner, Tobias
  • Hofmann, Carsten
  • Xiong, Chengjie
  • Bateman, Randall J
  • McDade, Eric
  • Clifford, David B
  • Mills, Susan L
  • Santacruz, Anna M
  • Aschenbrenner, Andrew J
  • Hassenstab, Jason

publication date

  • January 1, 2022